Higher Levels of Autoantibodies Targeting Mutated Citrullinated Vimentin in Patients with Psoriatic Arthritis Than in Patients with Psoriasis Vulgaris
Table 1
Basic demographic and clinical characteristics of psoriatic arthritis (PsA) and psoriasis (PsO) groups.
Variable
PsA group ()
PsO group ()
Male : female ratio
24 : 22
31 : 11
Age (mean ± SD; years)
54.35 ± 11.87
45.60 ± 15.72
BMI (mean ± SD; kg/m2)
29.38 ± 6.41
28.86 ± 9.80
Current smokers (%)
20
12
Age at diagnosis of PsO (mean ± SD; years)
38.91 ± 14.47
28.84 ± 15.82
Age at diagnosis of PsA (mean ± SD; years)
45.26 ± 13.80
—
Disease course severity (mild : moderate to severe)•
0 : 46
6 : 36
Psoriasis guttata (%)
4
20
Arthritis mutilans (%)
2
—
Axial arthritis (%)
17
—
Distal arthritis (%)
4
—
Asymmetrical oligoarthritis (%)
54
—
Symmetrical polyarthritis (%)
43
—
Therapy
Received MTX therapy (%)
85
57
Received systemic steroid treatment (%)
13
2
Received 311 nm NB-UVB therapy (%)
7
38
Received PUVA therapy (%)
2
31
Received biological therapy (%)
13
52
PsO: psoriasis vulgaris, PsA: psoriatic arthritis, BMI: body mass index, MTX: methotrexate, PUVA: psoralen + ultraviolet A, 311 nm NB-UVB: 311-nanometer narrow-band ultraviolet B. Symmetrical arthritis: bilateral arthritis with a frequency of >50%. •Patients previously or currently treated with DMARDs, systemic therapy or full-body phototherapy were regarded as “moderate-to-severe” patients, whereas the others were considered to exhibit a “mild” disease course.
